The initiation of coverage by a major financial institution like Wells Fargo, especially with an Overweight rating and a significant price target, is likely to generate positive investor sentiment towards AnaptysBio in the short term. This could lead to an increase in stock price as investors may view the analyst's rating as a strong endorsement of the company's future prospects.